

**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*

**20-695/S-003**

**APPROVAL LETTER**



Food and Drug Administration  
Rockville MD 20857

NDA 20-695/S-003

SEP 23 1998

Glaxo Wellcome  
Attention: Betsy J. Waldheim  
Project Director, Regulatory Affairs  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, N. C. 27709

Dear Ms. Waldheim:

Please refer to your supplemental new drug application dated March 31, 1998, received April 1, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Raxar® (grepafloxacin hydrochloride) tablets, 200 mg.

We acknowledge receipt of your amendment dated September 22, 1998.

This supplemental new drug application, as amended, provides for the addition of Legionella pneumophila to the *in vitro* listing in the Microbiology section of the package insert.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted September 22, 1998). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-695/S-003." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Robin Anderson, Project Manager, at (301) 827-2127.

Sincerely,

/S/

Mark J. Goldberger, M.D. M.P.H.  
Director  
Division of Special Pathogen and Immunologic Drug  
Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

**APPEARS THIS WAY  
ON ORIGINAL**

**NDA 20-695/S-004, S-005, S-006, S-007  
NDA 20-695/S-003 FA**

Glaxo Wellcome Inc.  
Attention: Betsy Waldheim  
Project Director, Regulatory Affairs  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709

Dear Ms. Waldheim:

Please refer to your supplemental new drug application 005 dated July 21, 1998, received July 22, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for RAXAR<sup>®</sup> (grepafloxacin tablets) Tablets, 200 mg, 400 mg, 600 mg

We acknowledge receipt of your submissions dated March 5, 1999, April 30, 1999, May 4, 1999, August 19, 1999, September 7, 1999, received March 8, 1999, May 3, 1999, May 5, 1999, August 20, 1999, September 8, 1999.

This supplemental new drug application provides for the following changes to the RAXAR<sup>®</sup> Tablets label:

**1. WARNINGS:**

- The word "Children" was changed to "Pediatric Patients" in the first sentence of the first paragraph.
- The first sentence in the second paragraph was revised to read:

"Convulsions have been reported in patients receiving quinolones, including grepafloxacin.

**2. PRECAUTIONS:**

- Another bullet was added to the Information for Patients subsection to read as follows:

"that convulsions have been reported in patients taking quinolones, including grepafloxacin, and to notify their physician before taking this drug if there is a history of this condition."

- In the Pediatric Use subsection the word "children" was changed to "pediatric patients."

**NDA 20-695/S-004, S-005, S-006, S-007**

**NDA 20-695/S-003 FA**

page 2

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (FPL) (package insert dated August, 1999). Accordingly, these supplemental applications are approved effective on the date of this letter.

The changes being effected (CBE) proposed in S- 004, S-006, and S-007 were included in the draft labeling submitted for S-003 and were approved as S-003 on September 23, 1998. Therefore, S-004, S-006, and S-007 are being acknowledged and retained but no further action is needed.

We note that when supplements for CBE are submitted, FPL should be included and the exact implementation date should be noted in the cover letter of those submissions.

The FPL for S-003 submitted on October 2, 1998 was not identical to the draft labeling approved for S-003 on September 23, 1998. The FPL submitted for S-003 is superseded by the FPL approved for S-005.

Please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

**NDA 20-695/S-004, S-005, S-006, S-007**

**NDA 20-695/S-003 FA**

page 3

If you have any questions, contact Robin Anderson, Regulatory Review Officer, at (301) 827-2127.

Sincerely,

Mark J. Goldberger, M.D., M.P.H.  
Director  
Division of Special Pathogen and Immunologic Drug  
Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

**APPEARS THIS WAY  
ON ORIGINAL**